Friday, October 16, 2026

BanColombia S.A. And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

ViaNews Editorial Team

December 14, 2020

BanColombia S.A. And 6 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Here is a list of stocks with an above 10% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Western Alliance Bancorporation

15.8% sales growth and 14.35% return on equity

Western Alliance Bancorporation sales growth this year is anticipated to be 11.2% and 4.8% for next year.

Year-on-year quarterly revenue growth grew by 3.1%, now sitting on 1.03B for the twelve trailing months.

Western Alliance Bancorporation's sales growth for the next quarter is 15.8%. The company's growth estimates for the ongoing quarter and the next is 4.8% and 48.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.35%.

Western Alliance Bancorporation's Stock Top and Bottom Yearly Value

Western Alliance Bancorporation's stock is valued at $58.13 at 16:57 EST, below its 52-week high of $59.38 and way higher than its 52-week low of $20.90.

Western Alliance Bancorporation's Moving Average

Western Alliance Bancorporation's worth is way higher than its 50-day moving average of $50.12 and way above its 200-day moving average of $40.04.

2. Horizon Therapeutics Public Limited Company

82.2% sales growth and 29.59% return on equity

Horizon Therapeutics Public Limited Company sales growth this year is expected to be 64.1% and 38.3% for next year.

Year-on-year quarterly revenue growth grew by 89.7%, now sitting on 1.82B for the twelve trailing months.

Horizon Therapeutics Public Limited Company's sales growth for the next quarter is 82.2%. The company's growth estimates for the ongoing quarter and the next is 82.1% and 150%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.59%.

Horizon Therapeutics Public Limited Company's Stock Top and Bottom Yearly Value

Horizon Therapeutics Public Limited Company's stock is valued at $75.57 at 16:57 EST, way below its 52-week high of $86.67 and way higher than its 52-week low of $23.81.

Horizon Therapeutics Public Limited Company's Moving Average

Horizon Therapeutics Public Limited Company's value is higher than its 50-day moving average of $72.87 and way above its 200-day moving average of $67.78.

3. SPS Commerce, Inc.

10.8% sales growth and 11.16% return on equity

SPS Commerce, Inc. sales growth this year is anticipated to be 11% and 9.6% for next year.

Year-on-year quarterly revenue growth grew by 12.2%, now sitting on 302.06M for the twelve trailing months.

SPS Commerce, Inc.'s sales growth for the next quarter is 10.8%. The company's growth estimates for the present quarter and the next is a negative 2.9% and negative -2.6%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.16%.

SPS Commerce, Inc.'s Stock Top and Bottom Yearly Value

SPS Commerce, Inc.'s stock is valued at $98.75 at 16:57 EST, below its 52-week high of $104.99 and way above its 52-week low of $31.28.

SPS Commerce, Inc.'s Moving Average

SPS Commerce, Inc.'s value is above its 50-day moving average of $93.84 and way higher than its 200-day moving average of $80.75.

4. Capital City Bank Group

28.1% sales growth and 12.48% return on equity

Capital City Bank Group sales growth this year is expected to be 36.3% and a negative 2.3% for next year.

Year-on-year quarterly revenue growth grew by 49.5%, now sitting on 188.94M for the twelve trailing months.

Capital City Bank Group's sales growth for the next quarter is 28.1%. The company's growth estimates for the present quarter and the next is a negative 2% and 76%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.48%.

Capital City Bank Group's Stock Top and Bottom Yearly Value

Capital City Bank Group's stock is valued at $25.55 at 16:57 EST, way below its 52-week high of $30.95 and way higher than its 52-week low of $15.61.

Capital City Bank Group's Moving Average

Capital City Bank Group's worth is way above its 50-day moving average of $23.16 and way above its 200-day moving average of $20.82.

5. BanColombia S.A.

42.3% sales growth and 3.58% return on equity

BanColombia S.A. sales growth this year is anticipated to be 14.7% and 2% for next year.

Year-on-year quarterly revenue growth declined by 0%, now sitting on N/A for the twelve trailing months.

BanColombia S.A.'s sales growth for the next quarter is 42.3%. The company's growth estimates for the ongoing quarter and the next is a negative 68.4% and 2.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.58%.

BanColombia S.A.'s Stock Top and Bottom Yearly Value

BanColombia S.A.'s stock is valued at $37.34 at 16:57 EST, way under its 52-week high of $56.10 and way above its 52-week low of $16.27.

BanColombia S.A.'s Moving Average

BanColombia S.A.'s value is way higher than its 50-day moving average of $29.55 and way higher than its 200-day moving average of $27.85.

6. Provident Bancorp, Inc.

14.8% sales growth and 5.45% return on equity

Provident Bancorp, Inc. sales growth this year is expected to be 23% and 4.4% for next year.

Year-on-year quarterly revenue growth grew by 25.6%, now sitting on 47.86M for the twelve trailing months.

Provident Bancorp, Inc.'s sales growth for the next quarter is 14.8%. The company's growth estimates for the current quarter and the next is 35.7% and 57.1%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.45%.

Provident Bancorp, Inc.'s Stock Top and Bottom Yearly Value

Provident Bancorp, Inc.'s stock is valued at $11.48 at 16:57 EST, way under its 52-week high of $12.92 and way higher than its 52-week low of $7.21.

Provident Bancorp, Inc.'s Moving Average

Provident Bancorp, Inc.'s worth is way higher than its 50-day moving average of $9.44 and way higher than its 200-day moving average of $8.43.

7. Spirit of Texas Bancshares, Inc.

13.8% sales growth and 7.72% return on equity

Spirit of Texas Bancshares, Inc. sales growth this year is anticipated to be 28.1% and 0.9% for next year.

Year-on-year quarterly revenue growth grew by 26.7%, now sitting on 105.82M for the twelve trailing months.

Spirit of Texas Bancshares, Inc.'s sales growth for the next quarter is 13.8%. The company's growth estimates for the present quarter and the next is 70.8% and 54.5%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.72%.

Spirit of Texas Bancshares, Inc.'s Stock Top and Bottom Yearly Value

Spirit of Texas Bancshares, Inc.'s stock is valued at $16.70 at 16:57 EST, way under its 52-week high of $23.48 and way higher than its 52-week low of $8.96.

Spirit of Texas Bancshares, Inc.'s Moving Average

Spirit of Texas Bancshares, Inc.'s value is way higher than its 50-day moving average of $15.03 and way higher than its 200-day moving average of $12.87.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com